• Protocols

• EAY191N4

  OPEN TO ACCRUAL

  Ph2 Randomized Selumetinib, Olaparib or Selumetinib in Patients w/Ovarian and Endometrial Cancer
  
  

• NRGGY026

  OPEN TO ACCRUAL

  Phase II/III Paclitaxel/Carboplatin +/- HERCEPTIN HYLECTA or PHESGO in HER2+ Stage I-IV Endometrial